Zymeworks (ZYME) has released an update.
Zymeworks has announced the dosing of the first patient in a Phase 1 trial for its investigational therapy ZW171, targeting advanced cancers with mesothelin expression. The trial aims to evaluate the safety and tolerability of ZW171 in ovarian and non-small cell lung cancers, with promising preclinical results showing strong anti-tumor activity.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
